Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease
- 1 August 2008
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 12 (4) , 256-263
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney diseaseClinical and Experimental Nephrology, 2007
- Preventing end-stage renal disease: flexible strategies to overcome obstaclesCurrent Opinion in Nephrology and Hypertension, 2006
- Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)Hypertension Research, 2006
- Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Angiotensin Inhibition Reduces Glomerular Damage and Renal Chemokine Expression in MRL/lpr MiceThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Angiotensin Type 1 Receptor Antagonism and ACE Inhibition Produce Similar Renoprotection inNω-Nitro-l>-Arginine Methyl Ester/Spontaneously Hypertensive RatsHypertension, 2001
- Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal ImpairmentHypertension, 1998
- A method for estimating nitrogen intake of patients with chronic renal failureKidney International, 1985